NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Highly Specialised Technologies Evaluation Committee (HSTEC) meeting minutes

**Minutes:** Confirmed

**Date:** Thursday 16 January 2025

**Location:** Via Zoom

## Attendees

Committee members present

1. Dr Paul Arundel (Chair) Present for all items
2. Professor Iolo Doull (Vice Chair) Present for all items
3. Annett Blochberger Present for all items
4. Emtiyaz Chowdhury Items 5.1 to 5.2.2
5. Carrie Gardner Items 1.1 to 4.2.2
6. Tina Garvey Items 1.1 to 4.2.2
7. Professor Jonathan Ives Present for all items
8. Professor Dusko Ilic Present for all items
9. Stuart Mealing Present for all items
10. Sara Payne Present for all items
11. Angharad Shambler Present for all items
12. Professor Ed Wilson Items 5.1 to 5.2.2

*Natalia Kunst (Observing) Items 1.1 to 4.2.2*

NICE staff (key players) present

Emily Crowe, Associate Director Items 1.1 to 4.2.2

Jeremy Powell, Project Manager Items 1.1 to 4.2.2

Albany Chandler, Health Technology Assessment Adviser Items 1.1 to 4.2.2

Luke Cowie, Health Technology Assessment Analyst Items 1.1 to 4.2.2

Enna Christmas, Health Technology Assessment Analyst Items 1.1 to 4.2.2

Ross Dent, Associate Director Items 5.1 to 5.2.2

Louise Jafferally, Project Manager Items 5.1 to 5.1.3

Alan Moore, Health Technology Assessment Adviser Items 5.1 to 5.2.2

Anita Sangha, Health Technology Assessment Analyst Items 5.1 to 5.2.2

External assessment group representatives present

Dawn Lee, PenTAG Items 1.1 to 4.1.3

Max Barnish, PenTAG Items 1.1 to 4.1.3

Paul Tappenden, ScHARR Items 5.1 to 5.1.3

Gamze Nalbant, ScHARR Items 5.1 to 5.1.3

Clinical, Patient & NHS England experts present

Helen West, Public Patient Involvement and Engagement Officer, patient expert nominated by Guts UK Charity Items 1.1 to 4.1.3

Jenny Seligmann, Professor of Gastrointestinal Oncology; Honorary Consultant Medical Oncologist, clinical expert nominated by Bristol Meyers Squibb (company) Items 1.1 to 4.1.3

Richard Wilson, Professor of Gastrointestinal Oncology; Honorary Consultant in Medical Oncology, clinical expert nominated by NICE Items 1.1 to 4.1.3

Professor Peter Clark, CDF Clinical Lead, NHS England Items 1.1 to 5.2.2

Dr Nick Morley, Haematology Consultant and Clinical Director, clinical expert, nominated by Amgen UK Items 5.1 to 5.1.3

Dr Bela Wrench, Consultant Haemato-oncologist, clinical expert, nominated by the Royal College of Pathologists Items 5.1 to 5.1.3

Calum Goodfellow, Policy Officer, Leukaemia Care, patient expert, nominated by Leukaemia Care Items 5.1 to 5.1.3

*Please note that alongside the attendees listed in this document, there were additional NICE Staff present in this meeting. These attendees were not involved in the decision making or discussions.*

## Minutes

### Introduction to the meeting

* 1. The Chair, Dr Paul Arundel, welcomed members of the committee and other attendees present to the meeting.
	2. The Chair noted apologies from Professor Ed Wilson, Emtiyaz Chowdhury, Carrier Gardner, Tina Garvey and Dr Shehla Mohammed.

### News and announcements

* 1. The Chair welcomed a new committee member, Dr Natalia Kunst, who is observing the January meeting and will be joining the committee in February.

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meetings held on Thursday 15 August 2024, Thursday 05 September 2024, Thursday 10 October 2024 and Thursday 07 November 2024.

### Appraisal of nivolumab with ipilimumab for untreated unresectable or metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID1136]

* 1. Part 1 – Open session
		1. The Chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Bristol Meyers Squibb.
		2. The Chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta10165/documents).
		3. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Tina Garvey, Angharad Shambler and Stuart Mealing.
	2. Part 2 – Closed session (company representatives, clinical and patient experts, external assessment group representatives and members of the public were asked to leave the meeting)
		1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10165>

### Appraisal of blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive B-precursor acute lymphoblastic leukaemia with no minimal residual disease [ID6405]

* 1. Part 1 – Open session
		1. The Chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Amgen.
		2. The Chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta11571/documents).
		3. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Jonathan Ives, Professor Dusko Ilic and Emtiyaz Chowdhury.
	2. Part 2 – Closed session (company representatives, clinical and patient experts, external assessment group representatives and members of the public were asked to leave the meeting)
		1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta11571>

### Date of the next meeting

The next meeting of the Highly Specialised Technologies Evaluation Committee (HSTEC) will be held on Thursday 6February 2025 and will start promptly at 9am.